Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company‚Äôs equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2023-01-23
3:48 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
Cowen Financial Products LLC3,647,430
7.05%
567,078increase
(+18.41%)
View
2022-04-22
10:54 am
Purchase
13GJounce Therapeutics, Inc.
JNCE
Cowen Financial Products LLC3,080,352
5.96%
3,080,352increase
(New Position)
View
2022-02-14
4:52 pm
Sale
13GJounce Therapeutics, Inc.
JNCE
Third Rock Ventures II, L.P.4,130,467
8.1%
-8,209,361decrease
(-66.53%)
View
2022-02-14
12:37 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
PFM Health Sciences, LP3,972,868
7.8%
1,584,801increase
(+66.36%)
View
2022-02-14
08:56 am
Purchase
13GJounce Therapeutics, Inc.
JNCE
Deep Track Capital, LP4,000,000
7.81%
143,537increase
(+3.72%)
View
2022-02-14
08:55 am
Purchase
13GJounce Therapeutics, Inc.
JNCE
RTW INVESTMENTS LP2,863,198
5.6%
2,863,198increase
(New Position)
View
2022-02-11
4:27 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
ORBIMED ADVISORS LLC2,200,200
4.3%
2,200,200increase
(New Position)
View
2022-02-10
09:28 am
Sale
13GJounce Therapeutics, Inc.
JNCE
ADAGE CAPITAL PARTNERS GP, L.L.C.0
0%
-2,768,840decrease
(Position Closed)
View
2021-09-01
4:20 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
Deep Track Capital, LP3,856,463
7.53%
3,856,463increase
(New Position)
View
2021-04-05
5:26 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
BRISTOL MYERS SQUIBB CO
BMY
3,456,463
7.6%
3,456,463increase
(New Position)
View
2021-02-16
4:06 pm
Sale
13GJounce Therapeutics, Inc.
JNCE
Third Rock Ventures II, L.P.12,339,828
31%
-939,292decrease
(-7.07%)
View
2021-02-01
2:13 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
PFM Health Sciences, LP2,388,067
6%
2,388,067increase
(New Position)
View
2021-01-29
4:12 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
ADAGE CAPITAL PARTNERS GP, L.L.C.2,768,840
6.95%
2,768,840increase
(New Position)
View
2020-10-26
4:33 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
GILEAD SCIENCES Inc
GILD
5,539,727
13.9%
5,539,727increase
(New Position)
View
2019-02-14
5:22 pm
Sale
13GJounce Therapeutics, Inc.
JNCE
PFM Health Sciences, LP0
0%
-2,101,489decrease
(Position Closed)
View
2019-02-12
09:57 am
Sale
13GJounce Therapeutics, Inc.
JNCE
WELLINGTON MANAGEMENT GROUP LLP1,510,754
4.62%
-364,108decrease
(-19.42%)
View
2018-12-10
09:02 am
Sale
13GJounce Therapeutics, Inc.
JNCE
FMR LLC1,007,115
3.079%
-1,621,275decrease
(-61.68%)
View
2018-02-14
4:11 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
PFM Health Sciences, LP2,101,489
6.5%
359,281increase
(+20.62%)
View
2018-02-13
4:06 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
Third Rock Ventures II, L.P.13,279,120
41.2%
13,279,120increase
(New Position)
View
2018-02-08
12:03 pm
Purchase
13GJounce Therapeutics, Inc.
JNCE
WELLINGTON MANAGEMENT GROUP LLP1,874,862
5.81%
1,874,862increase
(New Position)
View